论文部分内容阅读
荷兰莱登大学医学中心的Ｂｒｅｅｄｖｅｌｄ教授指出,单克隆抗体的开发使不少治疗领域得益,现已在美国和/或欧洲注册临床试验的单克隆抗体已显示了其在一些治疗领域的潜能。单克隆抗体在抑制异源免疫疾病方面已显示疗效。ＯｒｔｈｏｃｌｏｎｅＯＫＴ3(ｍｕｒｏｍｏｎａｂＣＤ3)
Professor Breedveld at the University of Leiden Medical Center in the Netherlands pointed out that the development of monoclonal antibodies has benefited many therapeutic fields and the monoclonal antibodies now registered for clinical trials in the United States and / or Europe have shown their potential in some therapeutic fields. Monoclonal antibodies have shown efficacy in inhibiting heterologous immune diseases. OrthocloneOKT3 (muromonabCD3)